Cargando…
Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the er...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450496/ https://www.ncbi.nlm.nih.gov/pubmed/36092658 http://dx.doi.org/10.3389/fchem.2022.957572 |
_version_ | 1784784534391226368 |
---|---|
author | Hejabi, Faranak Abbaszadeh, Mohammad Sadegh Taji, Shirinsadat O’Neill, Andrew Farjadian, Fatemeh Doroudian, Mohammad |
author_facet | Hejabi, Faranak Abbaszadeh, Mohammad Sadegh Taji, Shirinsadat O’Neill, Andrew Farjadian, Fatemeh Doroudian, Mohammad |
author_sort | Hejabi, Faranak |
collection | PubMed |
description | In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the era of genome editing, the safe and effective delivery of CRISPR/Cas systems represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In addition, there are some challenges in the in vivo delivery to the targeted cells/tissues. Nanotechnology-based drug delivery systems can be employed to overcome this issue. This review discusses different types and forms of CRISPR/Cas systems and the current CRISPR/Cas delivery systems, including non-viral carriers such as liposomes, polymeric, and gold particles. The focus then turns to the viral nanocarriers which have been recently used as a nanocarrier for CRISPR/Cas delivery. |
format | Online Article Text |
id | pubmed-9450496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94504962022-09-08 Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems Hejabi, Faranak Abbaszadeh, Mohammad Sadegh Taji, Shirinsadat O’Neill, Andrew Farjadian, Fatemeh Doroudian, Mohammad Front Chem Chemistry In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the era of genome editing, the safe and effective delivery of CRISPR/Cas systems represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In addition, there are some challenges in the in vivo delivery to the targeted cells/tissues. Nanotechnology-based drug delivery systems can be employed to overcome this issue. This review discusses different types and forms of CRISPR/Cas systems and the current CRISPR/Cas delivery systems, including non-viral carriers such as liposomes, polymeric, and gold particles. The focus then turns to the viral nanocarriers which have been recently used as a nanocarrier for CRISPR/Cas delivery. Frontiers Media S.A. 2022-07-26 /pmc/articles/PMC9450496/ /pubmed/36092658 http://dx.doi.org/10.3389/fchem.2022.957572 Text en Copyright © 2022 Hejabi, Abbaszadeh, Taji, O’Neill, Farjadian and Doroudian. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Hejabi, Faranak Abbaszadeh, Mohammad Sadegh Taji, Shirinsadat O’Neill, Andrew Farjadian, Fatemeh Doroudian, Mohammad Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
title | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
title_full | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
title_fullStr | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
title_full_unstemmed | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
title_short | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
title_sort | nanocarriers: a novel strategy for the delivery of crispr/cas systems |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450496/ https://www.ncbi.nlm.nih.gov/pubmed/36092658 http://dx.doi.org/10.3389/fchem.2022.957572 |
work_keys_str_mv | AT hejabifaranak nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT abbaszadehmohammadsadegh nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT tajishirinsadat nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT oneillandrew nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT farjadianfatemeh nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT doroudianmohammad nanocarriersanovelstrategyforthedeliveryofcrisprcassystems |